Subject: juvenile idiopathic arthritis
Subject: Tocilizumab
Subject: children
Year: 2021
Type: Article
Title: Evaluation of pediatric patients with juvenile idiopathic arthritis treated with biological therapy tocilizumab (actemra)
Author: Neshkovska Shumenkovska Marija
Author: Sofijanova, Aspazija
Author: Kacarska, Rozana
Author: Kuzevska-Мaneva, Konstandina
Author: Gjurkova-Angelovska Beti
Author: Jovanovska Valentina
Abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic disease in childhood. It manifests a heterogenic group of symptoms of arthritis, lasting at least 6 weeks and it appears before the age of 16. Patients who had no good therapeutic response to conventional therapy with Methotrexate were treated with biological therapy. The aim of this paper was to evaluate 9 patients who were receiving Tocilizumab at the Department of Rheumocariology, University Clinic of Pediatric Diseases in Skopje. Materials and methods: Our study included 9 patients treated at our Department with biological therapy with Tocilizumab. Prior to initiation of the biological therapy, all patients underwent laboratory investigations, purified protein derivate (PPD) skin test for tuberculosis, X ray of the lungs and heart, and analysis of hepatitis markers. All patients were treated with amp. Actemra( Tocilizumab) 8mg/kg /tt i.v. Two of the patients had a severe form of the disease (one with severe systemic form and one with severe oligoarticular form of JIA). All presented patients had clinical remission of the disease. Conclusion: Therapy with tocilizumab in patients with juvenile idiopathic arthritis is a good therapeutic choice. The results obtained in our study have shown a significant therapeutic effect of tocilizumab even in severe forms of the disease
Publisher: Институт за јавно здравје на Република Македонија = Institute of public health of Republic of Macedonia
Relation: Архиви на јавно здравје = Archives of public health
Identifier: oai:repository.ukim.mk:20.500.12188/15318
Identifier: http://hdl.handle.net/20.500.12188/15318Identifier: 10.3889/aph.2021.6016
Identifier: 13
Identifier: 2
